Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias: A Meta-Analysis of 38 Randomized Controlled Trials.

ABSTRACT:

Background

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have shown promising results in reducing hospitalizations from heart failure (HF) and cardiovascular mortality. However, their effect on arrhythmia and sudden cardiac death (SCD) is not well established.

Objectives

The authors sought to evaluate the association between SGLT2i and the risk of arrhythmias and SCD in patients with type 2 diabetes mellitus, HF, or chronic kidney disease.

Methods

We performed a systematic literature search on PubMed, EMBASE, and Scopus for relevant randomized controlled trials from inception until February 10, 2023. ORs and 95% CIs were pooled using a random effect model.

Results

A total of 38 randomized controlled trials with 88,704 patients (48,435 in the SGLT2i group a

SUBMITTER: Jaiswal V 

PROVIDER: S-EPMC11904486 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature